Article in Cancer prevention research (Philadelphia, Pa.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Craig A ElmetsDepartment of Dermatology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. celmets@uabmc.edu.ORCID 0000-0001-7131-4697
Andrzej SlominskiDepartment of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Mohammad AtharDepartment of Dermatology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
University of Alabama at Birmingham · US
Funding
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
RXR Rexinoids for Cancer ChemopreventionP01CA210946 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RENFROW, MATTHEW B · 2017 to 2021
$7.3M
Mechanism of action and function of novel secosteroid 20(OH)D3 in the skinR01AR073004 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANDRZEJ T SLOMINSKI · 2018 to 2026
$2.9M
Topical Chemoprevention of Skin Cancer BiomarkersR01CA193885 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ELMETS, CRAIG A · 2016 to 2022
$1.7M
Chemoprevention of environmental UVB-induced skin cancer in immunosuppressed miceR01ES026219 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ATHAR, MOHAMMAD · 2016 to 2020
$1.7M
Significance of metabolic activation of lumisterol in the skinR01AR071189 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SLOMINSKI, ANDRZEJ T · 2017 to 2021
$1.6M
Mechanism of ultraviolet radiation induced immune toleranceR01AR072213 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI XU, HUI · 2018 to 2022
$1.6M
Integration of mucosal immune responses through the enteric nervous systemR21AI105047 · NIAID · ROCKEFELLER UNIVERSITY · PI MUCIDA, DANIEL S · 2013 to 2014
$466k
Canonical and non-canonical vitamin D activation pathways in systemic lupusR21AI149267 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RAMAN, CHANDER, SLOMINSKI, ANDRZEJ T · 2020 to 2021
$408k
CYP11A1-derived secosteroids as therapeutic agents in UVB induced skin cancerI01BX004293 · VA · BIRMINGHAM VA MEDICAL CENTER · PI SLOMINSKI, ANDRZEJ T · 2019 to 2025
Melanoma is a treatment-resistant cancer of melanocytes. There is a serious unmet need for chemopreventive agents that can inhibit their evolution from preexisting dysplastic nevi. Low-dose aspirin and NSAIDs are potential chemopreventive candidates because they inhibit the enzyme COX-2 which has a number of procarcinogenic effects. Unfortunately, the clinical trial reported by Okwundu and colleagues in this issue of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Challenge of Melanoma Chemoprevention. · full record | OpenQuestion